Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.710
-0.010 (-0.58%)
At close: Feb 27, 2026, 4:00 PM EST
1.670
-0.040 (-2.34%)
After-hours: Feb 27, 2026, 7:59 PM EST
Milestone Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
173.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Karyopharm Therapeutics | 146.07M |
| ProQR Therapeutics | 18.86M |
| Innate Pharma | 14.84M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Compugen | 6.90M |
| Fate Therapeutics | 6.65M |
| Rani Therapeutics Holdings | 1.20M |
MIST News
- 1 day ago - Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 17 days ago - Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - GlobeNewsWire
- 24 days ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire
- 6 weeks ago - Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense - Seeking Alpha
- 7 weeks ago - Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript - Seeking Alpha
- 2 months ago - Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire